2022 American Transplant Congress
Clinical Outcomes In A Large Transplant Cohort Hospitalized With COVID-19: Mycophenolate Mofetil (MMF) Utilization And Mortality Trends
*Purpose: To characterize demographics, treatment patterns, and outcomes among 3,998 transplant patients hospitalized for COVID-19 over 16 months of the pandemic (May ’20-Aug ’21).*Methods: Adult…2022 American Transplant Congress
Effect of Mycophenolate Mofetil Dosing on Antibody Response to SARS-CoV-2 Vaccination in Heart and Lung Transplant Recipients
1Johns Hopkins University, Baltimore, MD, 2University of Wisconsin-Madison, Madison, WI
*Purpose: Mycophenolate mofetil (MMF) use is associated with decreased antibody response to the SARS-CoV-2 mRNA vaccine series in heart and lung transplant recipients (HLTRs). Higher…2021 American Transplant Congress
Tolerability of Mycophenolate Mofetil in Elderly Kidney Transplant Recipients: A Retrospective Cohort Study
*Purpose: Optimal immunosuppression in elderly kidney transplant recipients (KTRs) is not well-defined, with MMF being poorly tolerated at standard doses. This study aims to compare…2021 American Transplant Congress
Dietary Intake and Mycophenolate Mofetil-related Diarrhea Following Kidney Transplantation
*Purpose: The treatment of Mycophenolate mofetil (MMF) related diarrhea in kidney transplants recipients involves providing lower MMF doses more frequently to maintain the same daily…2021 American Transplant Congress
ABCC2 Haplotypes Associations to Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients
*Purpose: Mycophenolic acid (MPA), exhibits interpatient pharmacokinetic (PK) variability attributed to enterohepatic circulation of the glucuronide metabolite (MPAG) to MPA. This is mediated by multidrug…2020 American Transplant Congress
Outcomes Associated with Mycophenolate Weight-Based Dosing in Varying Immunologic Risk Kidney Transplant Recipients
Tampa General Hospital, Tampa, FL
*Purpose: Mycophenolate acid (MPA) is traditionally dosed in kidney transplant recipients (KTR) using the FDA-approved fixed dosing which is irrespective of patient-specific variables such as…2020 American Transplant Congress
Conversion to Sirolimus to Prevent Recurrent Cytomegalovirus Infection/Disease: A Prospective and Randomized Trial
Hospital do Rim - UNIFESP, São Paulo, Brazil
*Purpose: Recurrent cytomegalovirus (CMV) infection occurs in 30-35% of kidney transplant recipients after completion of treatment and/or preemptive therapy. There is no consensus on the…2020 American Transplant Congress
Oral versus Intravenous Mycophenolate Mofetil Administration: A Single Center Experience on Incidence of Acute Kidney Injury
*Purpose: Mycophenolate mofetil (MMF) is one of the main immunosuppressive medications given in lung transplantation (LTx). It is given orally (PO) or intravenously (IV). In…2020 American Transplant Congress
A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression
*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to…2020 American Transplant Congress
The Role of mTOR Inhibitors on Cardiovascular Aging in Renal Transplanted Patients with Chronic Graft Dysfunction
*Purpose: Chronic Kidney Disease (CKD) is strongly associated with increased circulatory complications that can lead to accelerated cardiovascular aging. During CKD, persistent oxidative stress triggered…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »